



Iris Schrader

Kontakt

Iris Schrader

Publikationen (10)

Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jüeckstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. *Cancers (Basel)* 2022; 14

De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22:111.

Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. *Clin Cancer Res* 2020; 26:1896-1904.

Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. *Breast* 2018; 44:81-89.

Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. *Clin Cancer Res* 2017; 23:5384-5393.

Gerber B, Loibl S, Nekljudova V, Hauschild M, Huober J, Blohmer J, Kunz G, Jackisch C, Solbach C, Hanusch C, Kittel K, Schrader I, Eggemann H, Tesch H, Fasching P, Rezai M, Eidtmann H, von Minckwitz G, Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). *Ann Surg Oncol* 2014; 21:2517-24.

Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. *Breast Cancer Res Treat* 2013; 139:779-87.

von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012; 366:299-309.

von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40). *Breast Cancer Res Treat* 2011

Riethdorf S, von Minckwitz G, Untch M, Eidtmann H, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Roller M, Komor M, Loibl S, Rau T, Zhang L, Müller V, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. *Clin Cancer Res* 2010; 16:2634-45.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch